MK-4280A (favezelimab and pembrolizumab) Emerging Drug Insight and Market Forecast - 2032

“MK-4280A (favezelimab and pembrolizumab) Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about MK-4280A (favezelimab and pembrolizumab) for Metastatic Colorectal Cancer (mCRC) in the 7MM. A detailed picture of the MK-4280A (favezelimab and pembrolizumab) for Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the MK-4280A (favezelimab and pembrolizumab) for Metastatic Colorectal Cancer. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MK-4280A (favezelimab and pembrolizumab) market forecast, analysis for Metastatic Colorectal Cancer in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Metastatic Colorectal Cancer.

Drug Summary

MK-4280A is a humanized, immunoglobulin G4 (IgG4) monoclonal antibody (MAb) directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG3), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, the anti-LAG3 monoclonal antibody MK-4280 binds to LAG3 expressed on tumor-infiltrating lymphocytes (TILs) and blocks it's binding with major histocompatibility complex (MHC) class II molecules expressed on tumor cells. This activates antigen-specific T lymphocytes and enhances cytotoxic T-cell-mediated tumor cell lysis, which leads to a reduction in tumor growth. LAG3, a member of the immunoglobulin superfamily (IgSF), is expressed on various immune cells and negatively regulates both proliferation and activation of T cells. Its expression on TILs is associated with tumor-mediated immune suppression.

MK-4280A is a co-formulation of favezelimab (MK-4280) and pembrolizumab (MK-3475), developed by Merck. It is currently under investigation in a Phase III trial (NCT05064059) in previously treated metastatic PD-L1 positive colorectal cancer patients.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the MK-4280A (favezelimab and pembrolizumab) description, mechanism of action, dosage and administration, research and development activities in Metastatic Colorectal Cancer.
• Elaborated details on MK-4280A (favezelimab and pembrolizumab) regulatory milestones and other development activities have been provided in this report.
• The report also highlights the MK-4280A (favezelimab and pembrolizumab) research and development activity in Metastatic Colorectal Cancer in detail across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around MK-4280A (favezelimab and pembrolizumab).
• The report contains forecasted sales of MK-4280A (favezelimab and pembrolizumab) for Metastatic Colorectal Cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Metastatic Colorectal Cancer.
• The report also features the SWOT analysis with analyst views for MK-4280A (favezelimab and pembrolizumab) in Metastatic Colorectal Cancer.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MK-4280A (favezelimab and pembrolizumab) Analytical Perspective

In-depth MK-4280A (favezelimab and pembrolizumab) Market Assessment

This report provides a detailed market assessment of MK-4280A (favezelimab and pembrolizumab) in Metastatic Colorectal Cancer in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.

MK-4280A (favezelimab and pembrolizumab) Clinical Assessment

The report provides the clinical trials information of MK-4280A (favezelimab and pembrolizumab) in Metastatic Colorectal Cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Metastatic Colorectal Cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MK-4280A (favezelimab and pembrolizumab) dominance.
• Other emerging products for Metastatic Colorectal Cancer are expected to give tough market competition to MK-4280A (favezelimab and pembrolizumab) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MK-4280A (favezelimab and pembrolizumab) in Metastatic Colorectal Cancer.
• This in-depth analysis of the forecasted sales data of MK-4280A (favezelimab and pembrolizumab) from 2026 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MK-4280A (favezelimab and pembrolizumab) in Metastatic Colorectal Cancer.

 

Key Questions Answered

• What is the product type, route of administration and mechanism of action of MK-4280A (favezelimab and pembrolizumab)?
• What is the clinical trial status of the study related to MK-4280A (favezelimab and pembrolizumab) in Metastatic Colorectal Cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MK-4280A (favezelimab and pembrolizumab) development?
• What are the key designations that have been granted to MK-4280A (favezelimab and pembrolizumab) for Metastatic Colorectal Cancer?
• What is the forecasted market scenario of MK-4280A (favezelimab and pembrolizumab) for Metastatic Colorectal Cancer?
• What are the forecasted sales of MK-4280A (favezelimab and pembrolizumab) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Metastatic Colorectal Cancer and how are they giving competition to MK-4280A (favezelimab and pembrolizumab) for Metastatic Colorectal Cancer?
• Which are the late-stage emerging therapies under development for the treatment of Metastatic Colorectal Cancer?

This product will be delivered within 2 business days.